Fairvalue-Calculator Fairvalue-Calculator
EN DE

Caina Technology Co (301122) Fair Value & Analysis

Healthcare · CN · Market cap 3.0B CNY

Price¥27.06
Fair Value¥2.79
Upside-89.7%
Quality95/100
Evidence: Medium Range ¥2.69 – ¥2.90

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Caina Technology Co (301122) currently trades at ¥27.06, while our model-based Fair Value estimate is ¥2.79 — implying the stock looks roughly 89.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Caina Technology Co., Ltd. engages in the research, development, production, and sale of plastic particles, needle holders, needle tubes, rubber plugs and other packaging materials. It offers disposable sterile safe self-destructing syringes, disposable insulin syringes, disposable sterile insulin pen needles, disposable sterile blood collection needles, and other sterile medical devices. Caina Technology Co., Ltd. was founded in 2004 and is based in Jiangyin, China.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Caina Technology Co (301122) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥2.79 versus a price of ¥27.06 — about −90% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 301122?
Our 21-model fair value for Caina Technology Co is ¥2.79 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥27.06.
What is the quality score of 301122?
Caina Technology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.